Not Signed In -
Schilder's Disease |
|
|
Clinical Trial: A Multi-Center, Observational Safety Registry of Subjects with Idiopathic Parkinson''s Disease Previously Treated with Intraputaminal Infusion of Liatermin
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson''''s disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.
| Condition | Phase |
|---|---|
| Idiopathic Parkinson''''s Disease | Phase IV |
MedlinePlus related topics: Parkinson''''s Disease
Genetics Home Reference related topics: Parkinson disease
Study Type: Observational
Study Design: Natural History
Eligibility
Ages Eligible for Study: 35 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Subjects must have a diagnosis of bilateral, idiopathic Parkinson''''s Disease who have been enrolled and treated with intraputaminal infusion of liatermin in a previous Amgen/Medtronic-sponsored trial (protocols 20010109 or 20030160) or the Bristol open-label study
- At time of implant (Study 20030168), subjects need to have been 35 to 70 years of age
More Information
AmgenTrials clinical trials website
Center Watch Clinical Trials Listing Service
Study ID Numbers: 20040256
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00148369
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00148369
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
